Business Context and Reporting Period
This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on December 19, 2023. The report discloses a change in the company's independent registered public accounting firm. The registrant is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol MEIP.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no values provided for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Dismissal of Previous Auditor: The Board of Directors approved the dismissal of BDO USA, P.C. as the independent registered public accounting firm effective December 19, 2023.
- Engagement of New Auditor: The Board appointed Deloitte & Touche LLP as the new independent registered public accounting firm, effective December 26, 2023.
- Audit Opinion Status: BDO's reports for the fiscal years ended June 30, 2023, and 2022, did not contain adverse opinions, disclaimers, or qualifications.
- Disagreements: The company reported no disagreements with BDO regarding accounting principles, practices, or auditing scope during the two most recent fiscal years or the interim period through December 19, 2023.
Guidance, Risks, and Contingencies
Internal Control Over Financial Reporting: The filing references a previously disclosed material weakness in internal controls related to the accounting for revenue recognition on license agreements, which was identified as of June 30, 2022. The company states this material weakness was remediated as of June 30, 2023.
Consultations with New Auditor: The company confirmed that no consultations occurred with Deloitte regarding accounting principles or audit opinions during the fiscal year ended June 30, 2023, or the interim period through December 26, 2023.
Investor Verification Checklist
- Verify the transition timeline between BDO USA, P.C. and Deloitte & Touche LLP to ensure no gap in audit coverage.
- Review the remediation plan and testing results for the previously disclosed material weakness in revenue recognition controls.
- Confirm the content of the BDO letter (Exhibit 16.1) to ensure the former auditor agrees with the company's statements regarding the dismissal.
- Check subsequent filings (e.g., 10-K or 10-Q) for the first financial statements audited by Deloitte to assess any changes in accounting treatment.